Xenical Research Today is a free monthly online journal that collates and summarizes the latest research about Xenical, including details on orlistat, side-effects, obesity, weight loss, dieting.

The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.

Ghandi S, Aflatoonian A, Tabibnejad N, Moghaddam MH

Department of Obstetrics & Gynecology, Sabzevar University of Medical Sciences, Sabzevar, Iran, sedighe_ghandi@yahoo.com.

PURPOSE: Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome. METHODS: A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months. RESULTS: There was no significant difference in ovulation between the two treatment groups (30% vs 15%). Treatment with either drug showed a significant decline in body weight, BMI (Body Mass Index), and waist circumference, but the degree of decline in both groups was the same. Patients who were treated with orlistat, showed a significant reduction in total testosterone and serum lipid. Women in metformin group showed a significant reduction in serum LH. CONCLUSIONS: Both metformin and orlistat showed a similar effect on weight loss and ovulation rates.

Published 12 April 2011 in J Assist Reprod Genet.
Full-text of this article is available online (may require subscription).

Articles on Xenical published 12 April 2011:

The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.   J Assist Reprod Genet.

PURPOSE: Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome. METHODS: A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months. RESULTS: There was no significant ... [Abstract] [Full-text]

The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.   J Assist Reprod Genet.

PURPOSE: Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome. METHODS: A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months. RESULTS: There was no significant ... [Abstract] [Full-text]

Articles on Xenical published 7 April 2011:

The 2',4',6'-Trihydroxyacetophenone Isolated from Myrcia multiflora Has Antiobesity and Mixed Hypolipidemic Effects with the Reduction of Lipid Intestinal Absorption.   Planta Med.

This study evaluated the hypolipidemic and antiobesity effects of phloroacetophenone (2',4',6'-trihydroxyacetophenone, THA) isolated from MYRCIA MULTIFLORA and their relationship with triglyceride (TG) intestinal absorption and pancreatic lipase activity inhibition. The hypolipidemic effect of THA was evaluated by acute (Triton WR-1339 treatment) and chronic assay (high-fat diet treatment), the antiobesity effect was evaluated by chronic assay (high-fat diet treatment), while the inhibition of ... [Abstract] [Full-text]

The 2',4',6'-Trihydroxyacetophenone Isolated from Myrcia multiflora Has Antiobesity and Mixed Hypolipidemic Effects with the Reduction of Lipid Intestinal Absorption.   Planta Med.

This study evaluated the hypolipidemic and antiobesity effects of phloroacetophenone (2',4',6'-trihydroxyacetophenone, THA) isolated from MYRCIA MULTIFLORA and their relationship with triglyceride (TG) intestinal absorption and pancreatic lipase activity inhibition. The hypolipidemic effect of THA was evaluated by acute (Triton WR-1339 treatment) and chronic assay (high-fat diet treatment), the antiobesity effect was evaluated by chronic assay (high-fat diet treatment), while the inhibition of ... [Abstract] [Full-text]

The 2',4',6'-Trihydroxyacetophenone Isolated from Myrcia multiflora Has Antiobesity and Mixed Hypolipidemic Effects with the Reduction of Lipid Intestinal Absorption.   Planta Med.

This study evaluated the hypolipidemic and antiobesity effects of phloroacetophenone (2',4',6'-trihydroxyacetophenone, THA) isolated from MYRCIA MULTIFLORA and their relationship with triglyceride (TG) intestinal absorption and pancreatic lipase activity inhibition. The hypolipidemic effect of THA was evaluated by acute (Triton WR-1339 treatment) and chronic assay (high-fat diet treatment), the antiobesity effect was evaluated by chronic assay (high-fat diet treatment), while the inhibition of ... [Abstract] [Full-text]

Articles on Xenical published 5 April 2011:

Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.   Eur J Cardiovasc Prev Rehabil.

Background: Trials of weight-loss drugs indicate some benefits on lipids, blood glucose, or blood pressure levels. Since obesity is associated with increased cardiovascular (CV) medication use and pharmaceutical costs, weight-loss drug use could beneficially impact CV medication use. Objective: We examined the temporal associations between CV drugs use 3 years before and after the initiation of orlistat, a weight-loss drug. Design: An historical cohort study in the PHARMO pharmacy registry ... [Abstract] [Full-text]

Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.   Eur J Cardiovasc Prev Rehabil.

Background: Trials of weight-loss drugs indicate some benefits on lipids, blood glucose, or blood pressure levels. Since obesity is associated with increased cardiovascular (CV) medication use and pharmaceutical costs, weight-loss drug use could beneficially impact CV medication use. Objective: We examined the temporal associations between CV drugs use 3 years before and after the initiation of orlistat, a weight-loss drug. Design: An historical cohort study in the PHARMO pharmacy registry ... [Abstract] [Full-text]

Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.   Eur J Cardiovasc Prev Rehabil.

Background: Trials of weight-loss drugs indicate some benefits on lipids, blood glucose, or blood pressure levels. Since obesity is associated with increased cardiovascular (CV) medication use and pharmaceutical costs, weight-loss drug use could beneficially impact CV medication use. Objective: We examined the temporal associations between CV drugs use 3 years before and after the initiation of orlistat, a weight-loss drug. Design: An historical cohort study in the PHARMO pharmacy registry ... [Abstract] [Full-text]

© 2004-2011 Xenical Research Today. All Rights Reserved.